Paramus, NJ
In response to the many pharmaceutical, biotech, device and diagnostic companies seeking assistance with the new Food and Drug Administration (FDA) laws, the REMS Group LLC today announced its formation.
"We meet with our clients to review their product attributes, design a REMS program that will meet the FDA's high standards, and implement the REMS initiatives," said Nicole Stouffer, president of the REMS Group. "Our continual focus on enterprise and sales rep training and vital communications helps to ensure timely, successful product launches and continued marketing efforts."
During the drug application process, the FDA requires a REMS plan to ensure that the benefits of a drug outweigh the risks of the drug. In addition, the FDA may require the submission of a REMS for an already-approved drug if the FDA becomes aware of new safety information.
The FDA has since required REMS of various drugs in the new drug application process as well as in the post-approval environment. Notably, the FDA recently announced the first class-wide REMS requirements for opioid drugs.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.